Neuroblastoma, an embryonic cancer of the sympathetic nervous system, is the 
most common extracranial solid tumor in childhood. Dinutuximab (formerly called 
ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been 
shown to significantly improve survival rates in patients with high-risk 
neuroblastoma. However, the safe and effective use of dinutuximab therapy in 
these high-risk patients requires medical expertise in patient selection, 
treatment administration, and the monitoring and management of adverse events. 
Findings of the randomized phase III study (ANBL0032) led to the approval of 
dinutuximab for the treatment of children with high-risk neuroblastoma. 
Multi-institutional nursing approaches to implementing standard protocols ensure 
the effective management of high-risk neuroblastoma patients receiving 
dinutuximab immunotherapy. Understanding and implementing recommendations for 
the management of the clinically important and most common adverse events are 
essential to ensuring patient continuation of therapy and improving patient 
outcomes.